The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Macrocyclic peptides are disclosed having the general formula:
wherein R
3
, R
3
′, R
4
, R
6
, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C virus inhibitors having the general formula
are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
申请人:Bristol-Myers Squibb Company
公开号:EP2033654A1
公开(公告)日:2009-03-11
A process for resolving a mixture of alkyl ester enantiomers comprising contacting the mixture with an enzyme effective to preferentially promote the hydrolysis of one of the enatiomers characterized in that the contacting is conducted in the presence of a buffer.